U.S. Markets closed

Cellectar Biosciences, Inc. (CLRB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0100+0.0199 (+2.01%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9901
Bid0.9911 x 1400
Ask1.0000 x 4000
Day's Range0.9719 - 1.0200
52 Week Range0.8100 - 2.9800
Avg. Volume944,792
Market Cap53.254M
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-0.5930
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.58
  • GlobeNewswire

    Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

    FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview at the following upcoming conference: Oppenheimer Fall Healthcare Life Sciences & MedTech SummitPresentation Date:Monday, September 20, 2021Presentation Time:12:25PM Eastern TimeWebcast Li

  • Benzinga

    4 Penny Stocks Insiders Are Buying

    When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Ault Global The Trade: Ault Global Holdings, Inc. (NYSE: DPW) Executive Chairman Milton C. Ault III acquired a total of 50

  • Investopedia

    Penny Stocks to Buy Using Technical Analysis for September 2021

    If you've been meaning to invest in penny stocks and learn more about technical analysis, there's no better time than now.